28 May 2021
Geneva – On the anniversary of the Solidarity Call to Action and the establishment of the C-TAP initiative, the Medicines Patent Pool (MPP) reaffirms its commitment and support to C-TAP by offering its expertise in licensing, to ensure that no one, wherever they live, are left behind when it comes to access to COVID-19 health technologies. The last year has seen an unprecedented response in developing tools to fight COVID-19. Today, there is still much to be done to ensure equitable access to COVID-19 health technologies, and C-TAP has a pivotal role in addressing challenges in global manufacturing and supply, along with universal access. MPP welcomes the growing support from partners for this very much needed initiative.
> Special press conference to mark the first anniversary of the COVID-19 Technology Access Pool
More on C-TAP
Array ( [0] => Array ( [acf_fc_layout] => post_grid [show_latest_posts] => [post_grid_layout] => rectangular [background_colour] => bg-pale-yellow [posts_per_row] => 3 [posts_to_display_in_grid] => Array ( [0] => WP_Post Object ( [ID] => 45 [post_author] => 1 [post_date] => 2021-04-27 11:00:38 [post_date_gmt] => 2021-04-27 10:00:38 [post_content] => [post_title] => Disease Areas [post_excerpt] => While reaffirming its work in core areas – HIV, hepatitis C and tuberculosis – MPP has now expanded its mandate to new disease areas including cancer, cardiovascular disease, diabetes and COVID-19. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => disease-areas [to_ping] => [pinged] => [post_modified] => 2025-07-10 12:24:03 [post_modified_gmt] => 2025-07-10 10:24:03 [post_content_filtered] => [post_parent] => 9 [guid] => https://medicinespatentpool.org/what-we-do/disease-areas/ [menu_order] => 16 [post_type] => page [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 6441 [post_author] => 4 [post_date] => 2020-05-29 18:34:32 [post_date_gmt] => 2020-05-29 17:34:32 [post_content] => On 29th May 2020, following Solidarity Call to Action, the COVID-19 Technology Access Pool (C-TAP) was launched. C-TAP is an initiative aimed at making treatments, vaccines, tests, and other health technologies to fight COVID-19 accessible to all. The Medicines Patent Pool (MPP) looks forward to working collaboratively with all stakeholders to contribute to efforts to address the current COVID-19 crisis. One of the key elements of C-TAP is licensing any potential treatment, diagnostic, vaccine or other health technology to the UN-backed Medicines Patent Pool. MPP’s Board already temporarily expanded its mandate to COVID-19 treatments & technologies on 31st March 2020. Marking the launch, WHO and Costa Rica co-sponsored a high-level event addressed by the WHO Director General, President of Costa Rica as well as other delegates from countries, the UN, academia, industry and civil society, including MPP’s Executive Director Charles Gore. Watch the event here (Charles' intervention at 51:50). [post_title] => Launch of the COVID-19 Technology Access Pool (C-TAP) [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => launch-of-the-covid-19-technology-access-pool-c-tap [to_ping] => [pinged] => [post_modified] => 2020-07-09 16:05:09 [post_modified_gmt] => 2020-07-09 15:05:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://medicinespatentpool.org/?post_type=news-publications&p=6441 [menu_order] => 204 [post_type] => news-publications [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 6476 [post_author] => 4 [post_date] => 2020-05-14 16:00:51 [post_date_gmt] => 2020-05-14 15:00:51 [post_content] => On 14th May, 2020, Health Action International, Knowledge Ecology International, Medicines Law & Policy, Pharmaceutical Accountability Foundation, and Wemos convened a briefing in advance of the virtual 73rd session of the World Health Assembly. The session was moderated by Ellen ‘t Hoen, LLM, PhD, Director, Medicines Law & Policy; the Medicines Patent Pool (MPP)'s founding and former Executive Director, and included interventions from the following panelists:
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.